Showing results (121-130 of 149) with videos related to
Sort By:
Pageof 15
Acta Medica Okayama|April 21, 2018
High-dose Dexamethasone Therapy as the Initial Treatment for Idiopathic Thrombocytopenic Purpura: Protocol for a Multicenter, Open-label, Single Arm TrialKen Takase, Akiko Kada, Hiromi Iwasaki, et al.International Journal of Hematology|June 9, 2026
TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trialKoji Izutsu, Ayumi Fujimoto, Shinya Rai, et al.Ejhaem|July 18, 2022
Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patientsSatoshi Yamasaki, Akiko Kada, Ilseung Choi, et al.Leukemia & Lymphoma|November 10, 2020
Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in JapanSatoshi Yamasaki, Hiroatsu Iida, Isao Yoshida, et al.British Journal of Haematology|December 22, 2017
Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in NagasakiMakiko Horai, Shinya Satoh, Masatoshi Matsuo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II studyTakashi Ishida, Tatsuro Joh, Naokuni Uike, et al.British Journal of Haematology|March 4, 2015
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II studyTakashi Ishida, Tatsuro Jo, Shigeki Takemoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphomaHiroo Katsuya, Takeharu Yamanaka, Kenji Ishitsuka, et al.Cancer Science|September 17, 2020
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of NagasakiEo Toriyama, Tomoko Hata, Ken-Ichi Yokota, et al.Blood|September 13, 2015
Treatment and survival among 1594 patients with ATLHiroo Katsuya, Kenji Ishitsuka, Atae Utsunomiya, et al.Pageof 15